{"url_path":"/sec/drio/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1533998/0001104659-26-059676-index.html","accession_number":"0001104659-26-059676","cik":"0001533998","ticker":"DRIO","issuer_name":"DarioHealth Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1533998/0001104659-26-059676-index.html","primary_entity_key":"0001533998","primary_entity_name":"DarioHealth Corp."},"word_count":286,"has_tables":true,"body_markdown":"Item 1A.  Risk Factors.\n\nIn addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition, or future results.\n\nThere have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, except as noted below.\n\nWe believe our current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year from the issuance of these interim financial statements. This raises substantial doubt about our ability to continue as a going concern.\n\nWe believe that our current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year from the issuance of our interim financial statements. This raises substantial doubt about our ability to continue as a going concern and could materially limit our ability to raise additional funds through the issuance of equity or debt securities or otherwise. If we cannot continue as a going concern, our investors may lose their entire investment in our securities. Until we can generate significant revenues, we expect to satisfy our future cash needs through equity or debt financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate product development plans commercialization, sales and marketing, or other strategic initiatives.\n\n​\n\n​\n\n12\n\n[Table of Contents](#TOC)"}